Subscribe

AbbVie Inc. (ABBV)

USD248.00 -0.08 (-0.03%)
US NYSE S&P 500 Healthcare Drug Manufacturers - General
Address 1 North Waukegan Road 60064-6400
North Chicago, IL, US
CEO Robert A. Michael
Website abbvie.com
IPO 2013-01-02
CIK 1551152 ISIN US00287Y1091

Explore sections of this company profile

Also trades on Buenos Aires Stock Exchange · ABBV.BA (ARS) Deutsche Börse · 4AB.DE (EUR) Dusseldorf Stock Exchange · 4AB.DU (EUR) London Stock Exchange · 0QCV.L (USD) New York Stock Exchange · ABBV (USD)
Description

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

News Sentiment (7d)
78 Positive

3 articles

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Ticker Date Filing
Purchaser PCYC 2015-03-23 View

Index membership

IndexAddedRemovedStatus
S&P 500 2013-01-01 — Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD248.00 -0.08 (-0.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.31
Float Shares
1.77B
Free Float %
99.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.61% -1.04% -2.48% -10.87% -13.06% -11.25% +6.69% +37.80% +76.39% +224.50% +479.37%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (41 ratings, all time) Buy
Price Targets & DCF
Current price
248.00
Low 223.00 -10.1%
Consensus 256.69 +3.5%
Median 260.00 +4.8%
High 294.00 +18.5%
DCF (Unlevered) 143.21 -42.3%
DCF (Levered) 188.15 -24.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 73% Bullish
Rating 2026-05 Change
Strong Buy 8 0
Buy 16 0
Hold 9 0
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month 3
278.00
+12.1%
Last Quarter 8
269.63
+8.7%
Last Year 25
257.48
+3.8%
All Time 75
202.79
-18.2%
Quality scores
Altman Z-Score
2.46
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - General: +6.6%
    +8.6% ★ Q1'26: +12.4% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    -0.8% Q1'26: -45.8% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +14.4% Q1'26: +23.8% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +15.5% Q1'26: +31.6% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +10.1% Q1'26: +14.0% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - General: +0.0%
    +0.1% Q1'26: +0.1% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    3.92× Q1'26: 3.85× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.31) × ERP
WACC = 84% × Ke + 16% × Kd (4.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 143.21 Current price: 248.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
22 Rev. Ana.
18 EPS Ana. 		Dec 2027
21 Rev. Ana.
18 EPS Ana. 		Dec 2028
24 Rev. Ana.
12 EPS Ana. 		Dec 2029
23 Rev. Ana.
10 EPS Ana. 		Dec 2030
15 Rev. Ana.
5 EPS Ana.
Revenue
18.79B
est: 18.33B (+2.5%)
19.96B
est: 18.55B (+7.6%)
22.86B
est: 22.86B (0.0%)
25.64B
est: 25.70B (-0.2%)
28.22B
est: 28.00B (+0.8%)
32.75B
est: 32.82B (-0.2%)
33.27B
est: 33.25B (+0.0%)
45.80B
est: 45.64B (+0.4%)
56.20B
est: 56.23B (-0.1%)
58.05B
est: 58.27B (-0.4%)
54.32B
est: 55.00B (-1.2%)
56.33B
est: 56.04B (+0.5%)
61.16B
est: 60.97B (+0.3%)
67.28B
66.57B – 67.74B
+10.4% YoY
72.60B
70.36B – 73.93B
+7.9% YoY
77.78B
77.74B – 77.82B
+7.1% YoY
82.12B
80.12B – 83.29B
+5.6% YoY
83.93B
81.89B – 85.12B
+2.2% YoY
EBITDA
6.53B
est: 6.36B (+2.6%)
3.58B
est: 3.25B (+10.4%)
8.20B
est: 7.87B (+4.3%)
10.12B
est: 9.93B (+1.9%)
10.38B
est: 10.20B (+1.8%)
8.31B
est: 7.87B (+5.6%)
12.23B
est: 11.96B (+2.2%)
12.32B
est: 11.75B (+4.9%)
23.93B
est: 23.38B (+2.4%)
24.17B
est: 26.13B (-7.5%)
17.17B
est: 18.82B (-8.8%)
14.91B
est: 19.18B (-22.3%)
17.63B
est: 20.87B (-15.5%)
23.03B
22.78B – 23.19B
+10.4% YoY
24.85B
24.08B – 25.30B
+7.9% YoY
26.62B
26.61B – 26.64B
+7.1% YoY
28.11B
27.42B – 28.51B
+5.6% YoY
28.73B
28.03B – 29.14B
+2.2% YoY
EBIT
5.63B
est: 5.52B (+2.0%)
2.80B
est: 3.10B (-9.6%)
7.36B
est: 7.22B (+2.0%)
8.93B
est: 9.20B (-3.0%)
8.88B
est: 9.43B (-5.8%)
6.55B
est: 5.97B (+9.6%)
10.21B
est: 12.70B (-19.6%)
5.85B
est: 10.88B (-46.2%)
15.41B
est: 17.57B (-12.3%)
15.71B
est: 19.69B (-20.2%)
8.47B
est: 10.69B (-20.7%)
6.52B
est: 10.89B (-40.1%)
9.49B
est: 11.85B (-19.9%)
13.08B
12.94B – 13.17B
+10.4% YoY
14.11B
13.67B – 14.37B
+7.9% YoY
15.12B
15.11B – 15.12B
+7.1% YoY
15.96B
15.57B – 16.19B
+5.6% YoY
16.31B
15.92B – 16.54B
+2.2% YoY
Net Income
4.13B
est: 4.02B (+2.6%)
1.77B
est: 1.59B (+11.3%)
5.14B
est: 4.94B (+4.1%)
5.95B
est: 5.84B (+2.0%)
5.31B
est: 5.23B (+1.5%)
5.69B
est: 5.33B (+6.7%)
7.88B
est: 7.71B (+2.3%)
4.62B
est: 4.39B (+5.2%)
11.54B
est: 11.26B (+2.5%)
11.84B
est: 13.10B (-9.7%)
4.86B
est: 5.30B (-8.2%)
4.28B
est: 17.95B (-76.2%)
4.23B
est: 17.68B (-76.1%)
25.50B
24.85B – 26.16B
+44.2% YoY
29.15B
27.43B – 30.87B
+14.3% YoY
30.17B
24.42B – 35.92B
+3.5% YoY
34.67B
33.57B – 35.31B
+14.9% YoY
35.79B
34.66B – 36.45B
+3.2% YoY
SGA
5.35B
est: 5.22B (+2.6%)
7.72B
est: 7.19B (+7.5%)
6.39B
est: 6.12B (+4.4%)
5.88B
est: 5.75B (+2.3%)
6.30B
est: 6.16B (+2.2%)
7.40B
est: 7.22B (+2.5%)
6.94B
est: 6.79B (+2.2%)
11.30B
est: 10.79B (+4.7%)
12.35B
est: 12.10B (+2.0%)
15.26B
est: 13.43B (+13.7%)
12.87B
est: 13.32B (-3.3%)
14.75B
est: 13.57B (+8.7%)
14.01B
est: 14.76B (-5.1%)
16.29B
16.12B – 16.40B
+10.4% YoY
17.58B
17.03B – 17.90B
+7.9% YoY
18.83B
18.82B – 18.84B
+7.1% YoY
19.88B
19.40B – 20.16B
+5.6% YoY
20.32B
19.83B – 20.61B
+2.2% YoY
EPS
2.58
est: 2.98 (-13.4%)
1.11
est: 2.83 (-60.8%)
3.15
est: 4.29 (-26.6%)
3.65
est: 4.82 (-24.3%)
3.31
est: 5.56 (-40.5%)
3.69
est: 7.96 (-53.6%)
5.30
est: 8.92 (-40.6%)
2.73
est: 10.48 (-73.9%)
6.48
est: 12.68 (-48.9%)
6.65
est: 13.76 (-51.7%)
2.73
est: 3.00 (-8.9%)
2.40
est: 10.08 (-76.2%)
2.37
est: 9.94 (-76.2%)
14.23
14.01 – 14.74
+43.1% YoY
16.24
15.46 – 17.40
+14.2% YoY
17.89
13.76 – 20.25
+10.2% YoY
19.54
18.92 – 19.90
+9.2% YoY
20.17
19.54 – 20.55
+3.2% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-05-04 Evercore ISI Group Outperform Outperform Maintain
2026-05-01 Guggenheim Buy Buy Maintain
2026-04-30 Morgan Stanley Overweight Overweight Maintain
2026-04-23 Piper Sandler Overweight Overweight Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B- 3/5 4/5 4/5 4/5 1/5 1/5 1/5
2026-05-08 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C+ 2/5 4/5 1/5 4/5 1/5 1/5 1/5
2026-04-28 C+ 2/5 4/5 1/5 4/5 1/5 1/5 1/5
2026-04-27 C+ 2/5 4/5 1/5 4/5 1/5 1/5 1/5
2026-04-24 C+ 2/5 4/5 1/5 4/5 1/5 1/5 1/5
2026-04-23 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5
2026-04-22 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5
2026-04-21 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5
2026-04-20 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5
2026-04-17 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5
2026-04-16 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5
2026-04-15 C+ 2/5 4/5 1/5 5/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
19.16B
OE per share TTM
10.82
Owner's Yield
5.33%
Maintenance CapEx ratio
10.17%
Maint CapEx / Avg PPE
9.5%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1,930
Total invested
22.12B
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 The Vanguard Group - 23-1945930 146.31M 8.28% — 3.01M 138.83M 7.48M IA Pennsylvania 2022-02-09 ↗
2 (1) BlackRock, Inc. 128.20M 7.30% 111.06M — 128.20M — HC Delaware 2022-02-03 ↗
3 Capital Research Global Investors ** 86.60M 5.80% 86.60M — 86.60M — IA — 2020-02-14 ↗
4 AbbVie Inc. 720.9K 4.88% 720.9K — 720.9K — CO State of Delaware 2017-08-11 ↗
5 95-1411037 13.00 2.10% 37.92M — 37.92M — IA Delaware 2021-02-16 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
1,930
-2,278 vs prev Q
New positions
60
Closed positions
2,258
Increased
882
Reduced
813
Put/Call ratio
0.74
Calls held
71.0K
Puts held
52.7K
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 VANGUARD GROUP INC 180.78M +3.0M (+1.7%) 41.31B +150.8M (+0.4%) 10.10% +0.065 pp 0.60% -0.017 pp USD83.25 +174.5% 53 qtrs —
2 BLACKROCK, INC. 151.17M +5.2M (+3.6%) 34.54B +742.3M (+2.2%) 8.44% +0.204 pp 0.58% -0.008 pp USD197.94 +15.4% 6 qtrs —
3 STATE STREET CORP 80.94M +1.1M (+1.4%) 18.49B +12.3M (+0.1%) 4.52% +0.016 pp 0.62% -0.021 pp USD68.71 +232.5% 51 qtrs —
4 JPMORGAN CHASE & CO 52.39M -4.1M (-7.3%) 11.97B -1.1B (-8.5%) 2.93% -0.265 pp 0.75% -0.033 pp USD121.23 +88.5% 51 qtrs —
5 GEODE CAPITAL MANAGEMENT, LLC 44.63M +4.2M (+10.4%) 10.18B +845.4M (+9.1%) 2.49% +0.210 pp 0.63% +0.033 pp USD112.94 +102.3% 52 qtrs —
6 MORGAN STANLEY 40.04M -1.6M (-3.9%) 9.15B -495.6M (-5.1%) 2.24% -0.115 pp 0.55% -0.038 pp USD129.77 +76.1% 51 qtrs —
7 BANK OF AMERICA CORP /DE/ 25.82M +669.5K (+2.7%) 5.90B +76.3M (+1.3%) 1.44% +0.023 pp 0.43% +0.034 pp USD123.15 +85.5% 52 qtrs —
8 NORGES BANK 25.67M +25.7M (+100.0%) 5.87B +5.9B (+100.0%) 1.43% +1.434 pp 0.63% +0.627 pp USD228.49 +0.0% 1 qtrs NEW
9 CAPITAL RESEARCH GLOBAL INVESTORS 25.41M +177.4K (+0.7%) 5.81B -36.4M (-0.6%) 1.42% -0.005 pp 1.07% -0.024 pp USD112.50 +103.1% 51 qtrs —
10 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 25.17M -788.3K (-3.0%) 5.75B -257.4M (-4.3%) 1.41% -0.059 pp 0.89% -0.066 pp USD138.96 +64.4% 52 qtrs —
11 FMR LLC 22.61M +1.6M (+7.5%) 5.17B +295.6M (+6.1%) 1.26% +0.076 pp 0.26% +0.010 pp USD151.59 +50.7% 53 qtrs —
12 NORTHERN TRUST CORP 21.73M -312.3K (-1.4%) 4.97B -138.6M (-2.7%) 1.21% -0.030 pp 0.63% -0.020 pp USD73.58 +210.5% 51 qtrs —
13 WELLINGTON MANAGEMENT GROUP LLP 14.93M +4.4M (+41.7%) 3.41B +970.9M (+39.8%) 0.83% +0.239 pp 0.60% +0.171 pp USD222.93 +2.5% 38 qtrs —
14 FRANKLIN RESOURCES INC 14.88M +330.1K (+2.3%) 3.40B +31.0M (+0.9%) 0.83% +0.010 pp 0.83% -0.006 pp USD153.42 +48.9% 51 qtrs —
15 BANK OF NEW YORK MELLON CORP 13.50M +1.2M (+9.7%) 3.08B +236.1M (+8.3%) 0.75% +0.060 pp 0.55% -0.004 pp USD95.18 +140.1% 52 qtrs —
16 CAPITAL WORLD INVESTORS 13.07M +6.7M (+106.3%) 2.99B +1.5B (+103.6%) 0.73% +0.373 pp 0.41% +0.206 pp USD204.87 +11.5% 14 qtrs —
17 GOLDMAN SACHS GROUP INC 13.00M -399.6K (-3.0%) 2.97B -132.2M (-4.3%) 0.73% -0.030 pp 0.36% -0.015 pp USD148.26 +54.1% 53 qtrs —
18 UBS ASSET MANAGEMENT AMERICAS INC 12.92M +343.2K (+2.7%) 2.95B +40.0M (+1.4%) 0.72% +0.012 pp 0.62% -0.008 pp USD128.66 +77.6% 52 qtrs —
19 LEGAL & GENERAL GROUP PLC 12.13M +129.2K (+1.1%) 2.77B -7.1M (-0.3%) 0.68% +0.000 pp 0.61% -0.009 pp USD92.25 +147.7% 52 qtrs —
20 CAPITAL INTERNATIONAL INVESTORS 11.69M +989.2K (+9.2%) 2.67B +195.2M (+7.9%) 0.65% +0.049 pp 0.42% +0.019 pp USD153.17 +49.2% 51 qtrs —
21 UBS GROUP AG 10.53M -1.2M (-10.2%) 2.41B -307.9M (-11.3%) 0.59% -0.073 pp 0.39% -0.035 pp USD111.25 +105.4% 45 qtrs —
22 AMUNDI 10.45M -57.9K (-0.6%) 2.39B -31.1M (-1.3%) 0.58% -0.009 pp 0.65% -0.129 pp USD166.54 +37.2% 19 qtrs —
23 DEUTSCHE BANK AG\ 10.13M +673.7K (+7.1%) 2.31B +125.1M (+5.7%) 0.57% +0.032 pp 0.75% +0.020 pp USD146.22 +56.3% 50 qtrs —
24 AMERIPRISE FINANCIAL INC 10.06M +384.8K (+4.0%) 2.30B +57.5M (+2.6%) 0.56% +0.016 pp 0.52% +0.005 pp USD113.72 +100.9% 53 qtrs —
25 PRICE T ROWE ASSOCIATES INC /MD/ 9.83M -775.8K (-7.3%) 2.25B -209.6M (-8.5%) 0.55% -0.050 pp 0.24% -0.021 pp USD139.77 +63.5% 53 qtrs —
26 RAYMOND JAMES FINANCIAL INC 9.40M -160.0K (-1.7%) 2.15B -64.0M (-2.9%) 0.52% -0.015 pp 0.67% -0.043 pp USD181.22 +26.1% 5 qtrs —
27 WELLS FARGO & COMPANY/MN 9.15M +20.6K (+0.2%) 2.09B -23.1M (-1.1%) 0.51% -0.004 pp 0.38% -0.021 pp USD84.87 +169.2% 52 qtrs —
28 DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN 8.92M +2.4M (+37.3%) 2.04B +534.2M (+35.5%) 0.50% +0.132 pp 1.76% +0.443 pp USD202.53 +12.8% 37 qtrs —
29 NUVEEN, LLC 8.61M +524.5K (+6.5%) 1.97B +95.2M (+5.1%) 0.48% +0.025 pp 0.52% +0.021 pp USD210.68 +8.5% 4 qtrs —
30 DIMENSIONAL FUND ADVISORS LP 8.28M -628.9K (-7.1%) 1.89B -170.4M (-8.3%) 0.46% -0.040 pp 0.40% -0.046 pp USD102.31 +123.3% 51 qtrs —
31 INVESCO LTD. 8.11M +668.7K (+9.0%) 1.85B +130.1M (+7.6%) 0.45% +0.033 pp 0.28% +0.013 pp USD160.72 +42.2% 53 qtrs —
32 ROYAL BANK OF CANADA 7.89M -472.2K (-5.6%) 1.80B -133.4M (-6.9%) 0.44% -0.031 pp 0.29% -0.024 pp USD101.10 +126.0% 51 qtrs —
33 ALLIANCEBERNSTEIN L.P. 6.71M -571.4K (-7.8%) 1.53B -152.8M (-9.1%) 0.37% -0.036 pp 0.48% -0.047 pp USD155.85 +46.6% 52 qtrs —
34 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 6.56M -1.8M (-21.5%) 1.50B -436.1M (-22.5%) 0.37% -0.105 pp 0.48% -0.116 pp USD154.04 +48.3% 26 qtrs —
35 JANUS HENDERSON GROUP PLC 6.40M +1.5M (+29.8%) 1.46B +320.5M (+28.1%) 0.36% +0.079 pp 0.66% +0.134 pp USD160.84 +42.1% 52 qtrs —
36 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 5.89M +— (+0.0%) 1.35B -18.0M (-1.3%) 0.33% -0.004 pp 1.06% -0.080 pp USD41.12 +455.7% 52 qtrs —
37 SWISS NATIONAL BANK 4.84M -251.0K (-4.9%) 1.11B -72.9M (-6.2%) 0.27% -0.017 pp 0.66% -0.026 pp USD89.56 +155.1% 51 qtrs —
38 BARCLAYS PLC 4.84M +4.9K (+0.1%) 1.11B +151.1M (+15.8%) 0.27% -0.003 pp 0.27% +0.020 pp USD177.02 +29.1% 51 qtrs —
39 ENVESTNET ASSET MANAGEMENT INC 4.83M -470.5K (-8.9%) 1.10B -123.7M (-10.1%) 0.27% -0.029 pp 0.33% -0.026 pp USD124.22 +83.9% 51 qtrs —
40 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 4.20M -761.1K (-15.3%) 959.34M -189.0M (-16.5%) 0.23% -0.045 pp 0.55% -0.139 pp USD124.34 +83.8% 52 qtrs —
41 TD ASSET MANAGEMENT INC 4.16M -97.8K (-2.3%) 950.64M -35.3M (-3.6%) 0.23% -0.008 pp 0.76% -0.036 pp USD172.56 +32.4% 51 qtrs —
42 NORDEA INVESTMENT MANAGEMENT AB 4.15M -345.6K (-7.7%) 950.63M -62.5M (-6.2%) 0.23% -0.022 pp 0.82% -0.071 pp USD144.21 +58.4% 52 qtrs —
43 PNC FINANCIAL SERVICES GROUP, INC. 4.14M -152.5K (-3.6%) 946.62M -47.9M (-4.8%) 0.23% -0.011 pp 0.52% -0.086 pp USD68.68 +232.7% 51 qtrs —
44 SUMITOMO MITSUI TRUST HOLDINGS, INC. 4.10M -153.2K (-3.6%) 937.46M -48.0M (-4.9%) 0.23% -0.011 pp 0.55% -0.016 pp USD75.15 +204.0% 52 qtrs —
45 HSBC HOLDINGS PLC 4.06M +115.5K (+2.9%) 929.58M +16.6M (+1.8%) 0.23% +0.004 pp 0.47% -0.030 pp USD139.20 +64.1% 52 qtrs —
46 NATIONAL PENSION SERVICE 3.86M -78.0K (-2.0%) 881.22M -29.8M (-3.3%) 0.22% -0.007 pp 0.65% -0.055 pp USD121.30 +88.4% 46 qtrs —
47 LPL FINANCIAL LLC 3.85M +119.7K (+3.2%) 880.39M +16.0M (+1.8%) 0.22% +0.005 pp 0.24% -0.012 pp USD140.98 +62.1% 51 qtrs —
48 FEDERATED HERMES, INC. 3.80M -227.8K (-5.7%) 867.85M -64.3M (-6.9%) 0.21% -0.015 pp 1.45% -0.196 pp USD158.21 +44.4% 52 qtrs —
49 MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. 3.75M +183.6K (+5.1%) 860.53M +34.1M (+4.1%) 0.21% +0.008 pp 0.58% -0.012 pp USD157.49 +45.1% 53 qtrs —
50 SUSQUEHANNA INTERNATIONAL GROUP, LLP 3.65M -1.3M (-26.3%) 834.99M -313.6M (-27.3%) 0.20% -0.076 pp 0.10% -0.035 pp USD147.47 +54.9% 51 qtrs —
51 AMERICAN CENTURY COMPANIES INC 3.50M +179.1K (+5.4%) 798.78M +30.8M (+4.0%) 0.20% +0.008 pp 0.40% +0.011 pp USD153.76 +48.6% 51 qtrs —
52 BOSTON PARTNERS 3.40M -413.9K (-10.9%) 775.92M -107.1M (-12.1%) 0.19% -0.025 pp 0.80% -0.103 pp USD165.86 +37.8% 30 qtrs —
53 BANK OF MONTREAL /CAN/ 3.22M +245.8K (+8.3%) 736.02M +47.1M (+6.8%) 0.18% +0.012 pp 0.25% -0.009 pp USD136.37 +67.6% 51 qtrs —
54 ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. 3.21M -112.9K (-3.4%) 733.49M -35.9M (-4.7%) 0.18% -0.008 pp 1.04% -0.070 pp USD161.70 +41.3% 52 qtrs —
55 SCHRODER INVESTMENT MANAGEMENT GROUP 3.20M +395.0K (+14.1%) 731.94M +81.7M (+12.6%) 0.18% +0.020 pp 0.56% +0.053 pp USD158.34 +44.3% 51 qtrs —
56 BESSEMER GROUP INC 3.12M +361.3K (+13.1%) 711.80M +74.1M (+11.6%) 0.17% +0.019 pp 1.09% +0.118 pp USD172.99 +32.1% 51 qtrs —
57 BNP PARIBAS ARBITRAGE, SNC 3.12M +118.4K (+4.0%) 711.79M +17.9M (+2.6%) 0.17% +0.005 pp 0.32% -0.048 pp USD185.36 +23.3% 51 qtrs —
58 BAHL & GAYNOR INC 3.09M -61.7K (-2.0%) 706.61M -23.7M (-3.2%) 0.17% -0.005 pp 3.58% -0.050 pp USD127.21 +79.6% 51 qtrs —
59 MANUFACTURERS LIFE INSURANCE COMPANY, THE 2.98M +29.8K (+1.0%) 682.42M -1.8M (-0.3%) 0.17% 0.000 pp 0.56% -0.002 pp USD122.20 +87.0% 52 qtrs —
60 RHUMBLINE ADVISERS 2.96M -76.1K (-2.5%) 677.04M -26.7M (-3.8%) 0.17% -0.006 pp 0.55% -0.018 pp USD79.44 +187.6% 51 qtrs —
61 ASSENAGON ASSET MANAGEMENT S.A. 2.96M -267.5K (-8.3%) 675.85M -71.0M (-9.5%) 0.17% -0.017 pp 0.93% -0.091 pp USD184.29 +24.0% 24 qtrs —
62 PRINCIPAL FINANCIAL GROUP INC 2.87M -482.0 (0.0%) 655.45M -8.9M (-1.3%) 0.16% -0.002 pp 0.33% 0.000 pp USD100.79 +126.7% 52 qtrs —
63 CANADA PENSION PLAN INVESTMENT BOARD 2.79M -394.5K (-12.4%) 637.86M -99.9M (-13.5%) 0.16% -0.024 pp 0.43% -0.091 pp USD165.13 +38.4% 52 qtrs —
64 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 2.74M -49.8K (-1.8%) 626.65M -19.9M (-3.1%) 0.15% -0.004 pp 0.63% -0.036 pp USD65.54 +248.6% 52 qtrs —
65 FAYEZ SAROFIM & CO 2.58M +420.9K (+19.5%) 590.47M +89.6M (+17.9%) 0.14% +0.022 pp 1.42% +0.256 pp USD104.11 +119.5% 49 qtrs —
66 STIFEL FINANCIAL CORP 2.47M -5.5K (-0.2%) 563.85M -8.8M (-1.5%) 0.14% -0.002 pp 0.51% -0.016 pp USD93.73 +143.8% 48 qtrs —
67 VOYA INVESTMENT MANAGEMENT LLC 2.46M +5.0K (+0.2%) 562.17M -6.0M (-1.1%) 0.14% -0.001 pp 0.55% -0.013 pp USD181.64 +25.8% 51 qtrs —
68 TRUIST FINANCIAL CORP 2.40M +96.3K (+4.2%) 548.89M +15.0M (+2.8%) 0.13% +0.004 pp 0.73% +0.010 pp USD105.10 +117.4% 51 qtrs —
69 CI PRIVATE WEALTH, LLC 2.39M +43.8K (+1.9%) 546.40M +3.5M (+0.7%) 0.13% +0.001 pp 0.73% -0.121 pp USD159.52 +43.2% 13 qtrs —
70 DEKABANK DEUTSCHE GIROZENTRALE 3.05M +— (+0.0%) 541.23M -140.0M (-20.6%) 0.17% -0.002 pp 0.94% -0.211 pp USD110.95 +105.9% 52 qtrs —
71 US BANCORP \DE\ 2.36M -42.0K (-1.7%) 538.83M -16.9M (-3.0%) 0.13% -0.004 pp 0.63% -0.027 pp USD54.18 +321.7% 51 qtrs —
72 LOS ANGELES CAPITAL MANAGEMENT LLC 2.33M +7.3K (+0.3%) 532.08M -6.1M (-1.1%) 0.13% -0.001 pp 1.81% -0.013 pp USD198.89 +14.9% 52 qtrs —
73 ABRDN PLC 2.26M +4.2K (+0.2%) 516.31M +4.8M (+0.9%) 0.13% -0.001 pp 0.80% -0.010 pp USD134.45 +69.9% 34 qtrs —
74 MACKENZIE FINANCIAL CORP 2.08M -161.9K (-7.2%) 476.04M -42.2M (-8.1%) 0.12% -0.010 pp 0.56% -0.064 pp USD125.82 +81.6% 52 qtrs —
75 CITADEL ADVISORS LLC 2.03M -375.3K (-15.6%) 464.70M -93.1M (-16.7%) 0.11% -0.022 pp 0.07% -0.015 pp USD160.57 +42.3% 38 qtrs —
76 NEW YORK STATE COMMON RETIREMENT FUND 2.03M -34.2K (-1.7%) 462.81M -14.1M (-3.0%) 0.11% -0.003 pp 0.62% +0.001 pp USD53.99 +323.2% 52 qtrs —
77 ENSIGN PEAK ADVISORS, INC 2.01M -31.6K (-1.5%) 459.95M -13.5M (-2.8%) 0.11% -0.003 pp 0.81% +0.036 pp USD134.62 +69.7% 25 qtrs —
78 AGF MANAGEMENT LTD 1.99M +979.6K (+97.3%) 453.95M +220.8M (+94.7%) 0.11% +0.054 pp 1.97% +0.943 pp USD198.24 +15.3% 13 qtrs —
79 BAIRD FINANCIAL GROUP, INC. 1.97M -22.1K (-1.1%) 450.90M -11.1M (-2.4%) 0.11% -0.002 pp 0.70% -0.040 pp USD83.15 +174.8% 43 qtrs —
80 SWEDBANK AB 1.95M -11.0K (-0.6%) 446.12M -8.5M (-1.9%) 0.11% -0.002 pp 0.43% -0.029 pp USD132.87 +72.0% 20 qtrs —
81 NATIONAL BANK OF CANADA /FI/ 1.84M -70.0K (-3.7%) 420.65M -21.8M (-4.9%) 0.10% -0.005 pp 0.38% -0.058 pp USD174.17 +31.2% 17 qtrs —
82 MAN GROUP PLC 1.81M +518.8K (+40.2%) 413.27M +114.6M (+38.4%) 0.10% +0.028 pp 0.70% +0.183 pp USD187.72 +21.7% 32 qtrs —
83 BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. 1.74M +1.2M (+256.5%) 396.73M +284.9M (+254.7%) 0.10% +0.070 pp 0.46% +0.165 pp USD215.44 +6.1% 51 qtrs —
84 GREAT WEST LIFE ASSURANCE CO /CAN/ 1.72M -202.6K (-10.5%) 394.11M -35.7M (-8.3%) 0.10% -0.012 pp 0.69% +0.071 pp USD108.87 +109.9% 52 qtrs —
85 PRUDENTIAL FINANCIAL INC 1.72M -141.5K (-7.6%) 392.24M -38.0M (-8.8%) 0.10% -0.009 pp 0.47% -0.038 pp USD121.90 +87.4% 53 qtrs —
86 CITIGROUP INC 1.65M -1.1M (-39.1%) 377.39M -251.1M (-40.0%) 0.09% -0.061 pp 0.17% -0.114 pp USD147.24 +55.2% 52 qtrs —
87 HIGHTOWER ADVISORS, LLC 1.63M -12.9K (-0.8%) 372.19M -8.0M (-2.1%) 0.09% -0.002 pp 0.41% -0.025 pp USD108.83 +110.0% 52 qtrs —
88 CAISSE DE DEPOT ET PLACEMENT DU QUEBEC 1.62M +152.4K (+10.4%) 371.02M +30.3M (+8.9%) 0.09% +0.008 pp 0.63% +0.016 pp USD198.60 +15.1% 51 qtrs —
89 STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 1.57M -44.6K (-2.8%) 359.47M -15.1M (-4.0%) 0.09% -0.003 pp 0.64% -0.019 pp USD62.59 +265.1% 51 qtrs —
90 — 1.55M +1.6M (+100.0%) 355.45M +355.5M (+100.0%) 0.09% +0.087 pp 1.11% +1.106 pp USD228.49 +0.0% 1 qtrs NEW
91 UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH 1.54M +9.2K (+0.6%) 347.94M -6.3M (-1.8%) 0.09% 0.000 pp 0.56% -0.023 pp USD178.07 +28.3% 5 qtrs —
92 KOREA INVESTMENT CORP 1.52M -33.9K (-2.2%) 346.45M -12.5M (-3.5%) 0.08% -0.003 pp 0.68% -0.056 pp USD130.85 +74.6% 52 qtrs —
93 VICTORY CAPITAL MANAGEMENT INC 1.51M -15.6K (-1.0%) 345.03M -5.6M (-1.6%) 0.08% -0.002 pp 0.19% -0.010 pp USD120.39 +89.8% 45 qtrs —
94 ADAGE CAPITAL PARTNERS GP, L.L.C. 1.51M -336.1K (-18.2%) 344.73M -82.4M (-19.3%) 0.08% -0.020 pp 0.52% -0.155 pp USD156.16 +46.3% 23 qtrs —
95 FIFTH THIRD BANCORP 1.49M +12.1K (+0.8%) 340.72M -1.7M (-0.5%) 0.08% 0.000 pp 1.08% -0.013 pp USD77.82 +193.6% 51 qtrs —
96 CAPTRUST FINANCIAL ADVISORS 1.49M +13.1K (+0.9%) 339.98M -1.5M (-0.4%) 0.08% 0.000 pp 0.65% -0.050 pp USD148.67 +53.7% 35 qtrs —
97 AVIVA PLC 1.49M +79.5K (+5.7%) 339.55M +13.9M (+4.3%) 0.08% +0.004 pp 0.57% -0.019 pp USD153.69 +48.7% 51 qtrs —
98 NEW YORK STATE TEACHERS RETIREMENT SYSTEM 1.44M -39.2K (-2.6%) 329.27M -13.5M (-3.9%) 0.08% -0.003 pp 0.64% -0.028 pp USD51.90 +340.3% 51 qtrs —
99 ACTIAM N.V. 5.44M +4.9M (+914.6%) 124.41M +151.0K (+0.1%) 0.30% +0.274 pp 1.26% -0.062 pp USD226.54 +0.9% 4 qtrs —
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
2.72
Bullish
Ratio by volume
2.70
Bullish
Buys
49
Sells
18
Shares acquired
564.1K
Shares disposed
209.1K
Cash buys
—
Cash sales
5.00
Net activity
+354,967
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-03-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 155 217.49 33.7K 28,865 D ↗
2026-03-31 Quaggin Susan E Director A-Award A Stock Equivalent Units 71 217.49 15.4K 784 D ↗
2026-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 35 217.49 7.6K 10,369 D ↗
2026-03-04 Purdue David Ryan Officer S-Sale D Common Stock, $0.01 par value 5,230 233.56 1.22M 2,654 D ↗
2026-03-02 Siatis Perry C Officer S-Sale D Common Stock, $0.01 par value 5,777 233.51 1.35M 17,510 D ↗
2026-02-27 Thakkar Roopal Officer F-InKind D Common Stock, $0.01 par value 8,037 232.08 1.87M 52,376 D ↗
2026-02-27 Stewart Jeffrey Ryan Officer F-InKind D Common Stock, $0.01 par value 23,812 232.08 5.53M 83,171 D ↗
2026-02-27 Siatis Perry C Officer F-InKind D Common Stock, $0.01 par value 14,850 232.08 3.45M 23,287 D ↗
2026-02-27 SALEKI-GERHARDT AZITA Officer F-InKind D Common Stock, $0.01 par value 16,309 232.08 3.78M 197,794 D ↗
2026-02-27 Reents Scott T Officer F-InKind D Common Stock, $0.01 par value 21,638 232.08 5.02M 38,777 D ↗
2026-02-27 Purdue David Ryan Officer F-InKind D Common Stock, $0.01 par value 2,692 232.08 624.8K 7,884 D ↗
2026-02-27 Michael Robert A. Director / Officer F-InKind D Common Stock, $0.01 par value 36,523 232.08 8.48M 178,737 D ↗
2026-02-27 Donoghoe Nicholas Officer F-InKind D Common Stock, $0.01 par value 12,874 232.08 2.99M 74,430 D ↗
2026-02-27 Crum Demetris D Officer F-InKind D Common Stock, $0.01 par value 1,594 232.08 369.9K 7,914 D ↗
2026-02-25 Siatis Perry C Officer S-Sale D Common Stock, $0.01 par value 22,381 230.00 5.15M 38,137 D ↗
2026-02-18 Thakkar Roopal Officer A-Award A Common Stock, $0.01 par value 3,346 0.00 — 53,775 D ↗
2026-02-18 Stewart Jeffrey Ryan Officer A-Award A Common Stock, $0.01 par value 8,988 0.00 — 106,983 D ↗
2026-02-18 Siatis Perry C Officer A-Award A Option (Right to buy) 19,500 230.04 4.49M 19,500 D ↗
2026-02-18 SALEKI-GERHARDT AZITA Officer A-Award A Common Stock, $0.01 par value 17,041 0.00 — 194,333 D ↗
2026-02-18 Reents Scott T Officer A-Award A Common Stock, $0.01 par value 7,260 0.00 — 60,415 D ↗
2026-02-18 Purdue David Ryan Officer A-Award A Common Stock, $0.01 par value 2,505 0.00 — 7,010 D ↗
2026-02-18 Michael Robert A. Director / Officer A-Award A Common Stock, $0.01 par value 22,124 0.00 — 215,260 D ↗
2026-02-18 Donoghoe Nicholas Officer A-Award A Option (Right to buy) 20,312 230.04 4.67M 20,312 D ↗
2026-02-18 Crum Demetris D Officer A-Award A Option (Right to buy) 13,406 230.04 3.08M 13,406 D ↗
2025-12-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 147 228.49 33.6K 28,498 D ↗
2025-12-31 Quaggin Susan E Director A-Award A Stock Equivalent Units 68 228.49 15.5K 707 D ↗
2025-12-31 Alpern Robert J Director A-Award A Stock Equivalent Units 34 228.49 7.8K 10,257 D ↗
2025-09-30 RAPP EDWARD J Director A-Award A Stock Equivalent Units 145 231.54 33.6K 28,152 D ↗
2025-09-30 Quaggin Susan E Director A-Award A Stock Equivalent Units 67 231.54 15.5K 634 D ↗
2025-09-30 Alpern Robert J Director A-Award A Stock Equivalent Units 33 231.54 7.6K 10,151 D ↗
2025-08-12 SALEKI-GERHARDT AZITA Officer M-Exempt A Common Stock, $0.01 par value 42,370 54.86 2.32M 219,662 D ↗
2025-08-05 Donoghoe Nicholas Officer S-Sale D Common Stock, $0.01 par value 3,234 198.27 641.2K 68,308 D ↗
2025-07-01 Crum Demetris D Officer — — Option (Right to buy) 5,043 175.28 883.9K 0 D ↗
2025-07-01 AbbVie Inc. Officer — — Option (Right to buy) 4,687 192.86 903.9K 0 D ↗
2025-06-30 RAPP EDWARD J Director A-Award A Stock Equivalent Units 177 185.62 32.9K 27,785 D ↗
2025-06-30 Quaggin Susan E Director A-Award A Stock Equivalent Units 81 185.62 15.0K 562 D ↗
2025-06-30 Alpern Robert J Director A-Award A Stock Equivalent Units 40 185.62 7.4K 10,038 D ↗
2025-05-09 WADDELL FREDERICK H Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 28,958 D ↗
2025-05-09 TILTON GLENN F Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 51,564 D ↗
2025-05-09 Roberts Rebecca B Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 13,728 D ↗
2025-05-09 RAPP EDWARD J Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 34,458 D ↗
2025-05-09 Quaggin Susan E Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 2,525 D ↗
2025-05-09 MEYER MELODY B Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 16,498 D ↗
2025-05-09 Hart Brett J Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 19,472 D ↗
2025-05-09 FREYMAN THOMAS C Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 126,751 D ↗
2025-05-09 FALK THOMAS J Director — — Common Stock, $0.01 par value 0 0.00 — 1,203 D ↗
2025-05-09 Davis Jennifer L. Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 2,525 D ↗
2025-05-09 BURNSIDE WILLIAM H.L. Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 26,958 D ↗
2025-05-09 Alpern Robert J Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 35,646 D ↗
2025-05-09 AUSTIN ROXANNE S Director A-Award A Common Stock, $0.01 par value 1,203 0.00 — 38,458 D ↗
2025-03-31 Stewart Jeffrey Ryan Officer M-Exempt D Option (Right to Buy) 25,700 79.02 2.03M 0 D ↗
2025-03-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 155 209.52 32.5K 27,361 D ↗
2025-03-31 Quaggin Susan E Director A-Award A Stock Equivalent Units 71 209.52 14.9K 476 D ↗
2025-03-31 GONZALEZ RICHARD A Director G-Gift D Common Stock, $0.01 par value 2,450 0.00 — 386,479 D ↗
2025-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 35 209.52 7.3K 9,907 D ↗
2025-03-14 Reents Scott T Officer S-Sale D Common Stock, $0.01 par value 17,644 212.34 3.75M 11,577 D ↗
2025-03-03 Siatis Perry C Officer D-Return D Option (Right to buy) 7,775 175.28 1.36M 15,549 D ↗
2025-03-03 RICHMOND TIMOTHY J. Officer S-Sale D Common stock, $0.01 par value 5,677 209.80 1.19M 21,703 D ↗
2025-03-03 GONZALEZ RICHARD A Director S-Sale D Common Stock, $0.01 par value 6,168 210.53 1.30M 388,929 D ↗
2025-03-01 Purdue David Ryan Officer — — Option (Right to buy) 3,376 149.62 505.1K 0 D ↗
2025-02-28 Thakkar Roopal Officer F-InKind D Common Stock, $0.01 par value 4,678 205.02 959.1K 42,276 D ↗
2025-02-28 Stewart Jeffrey Ryan Officer F-InKind D Common Stock, $0.01 par value 20,226 205.02 4.15M 86,366 D ↗
2025-02-28 Siatis Perry C Officer S-Sale D Common Stock, $0.01 par value 363 207.19 75.2K 4,619 D ↗
2025-02-28 SALEKI-GERHARDT AZITA Officer F-InKind D Common Stock, $0.01 par value 17,056 205.02 3.50M 177,292 D ↗
2025-02-28 Reents Scott T Officer F-InKind D Common Stock, $0.01 par value 10,973 205.02 2.25M 29,221 D ↗
2025-02-28 RICHMOND TIMOTHY J. Officer F-InKind D Common stock, $0.01 par value 16,904 205.02 3.47M 27,380 D ↗
2025-02-28 Michael Robert A. Director / Officer F-InKind D Common Stock, $0.01 par value 27,186 205.02 5.57M 132,821 D ↗
2025-02-28 GONZALEZ RICHARD A Director F-InKind D Common Stock, $0.01 par value 73,209 205.02 15.01M 487,557 D ↗
2025-02-28 Donoghoe Nicholas Officer F-InKind D Common Stock, $0.01 par value 11,230 205.02 2.30M 70,018 D ↗
2025-02-28 Buckbee Kevin K Officer F-InKind D Common Stock, $0.01 par value 3,699 205.02 758.4K 7,797 D ↗
2025-02-26 RICHMOND TIMOTHY J. Officer M-Exempt A Common stock, $0.01 par value 22,210 114.36 2.54M 66,494 D ↗
2025-02-26 Buckbee Kevin K Officer S-Sale D Common Stock, $0.01 par value 2,684 203.40 545.9K 12,646 D ↗
2025-02-20 Siatis Perry C Officer S-Sale D Common Stock, $0.01 par value 1,784 197.40 352.2K 26,375 D ↗
2025-02-13 Thakkar Roopal Officer A-Award A Common Stock, $0.01 par value 3,348 0.00 — 46,954 D ↗
2025-02-13 Stewart Jeffrey Ryan Officer A-Award A Common Stock, $0.01 par value 9,432 0.00 — 106,592 D ↗
2025-02-13 Siatis Perry C Officer A-Award A Option (Right to buy) 21,875 192.86 4.22M 21,875 D ↗
2025-02-13 SALEKI-GERHARDT AZITA Officer A-Award A Option (Right to Buy) 25,000 192.86 4.82M 25,000 D ↗
2025-02-13 Reents Scott T Officer A-Award A Option (Right to buy) 27,343 192.86 5.27M 27,343 D ↗
2025-02-13 RICHMOND TIMOTHY J. Officer A-Award A Common stock, $0.01 par value 5,792 0.00 — 44,993 D ↗
2025-02-13 Michael Robert A. Director / Officer A-Award A Common Stock, $0.01 par value 14,454 0.00 — 160,007 D ↗
2025-02-13 GONZALEZ RICHARD A Director A-Award A Option (Right to Buy) 65,104 192.86 12.56M 65,104 D ↗
2025-02-13 Donoghoe Nicholas Officer A-Award A Common Stock, $0.01 par value 5,174 0.00 — 81,248 D ↗
2025-02-13 Buckbee Kevin K Officer A-Award A Common Stock, $0.01 par value 1,674 0.00 — 15,330 D ↗
2024-12-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 182 177.70 32.3K 26,976 D ↗
2024-12-31 Quaggin Susan E Director A-Award A Stock Equivalent Units 84 177.70 14.9K 401 D ↗
2024-12-31 Alpern Robert J Director A-Award A Stock Equivalent Units 42 177.70 7.5K 9,788 D ↗
2024-12-16 Buckbee Kevin K Officer M-Exempt D Option (Right to buy) 1,800 93.50 168.3K 12,111 D ↗
2024-09-30 RAPP EDWARD J Director A-Award A Stock Equivalent Units 164 197.48 32.4K 26,544 D ↗
2024-09-30 Quaggin Susan E Director A-Award A Stock Equivalent Units 75 197.48 14.8K 314 D ↗
2024-09-30 GONZALEZ RICHARD A Director / Officer G-Gift D Common Stock, $0.01 par value 5,243 0.00 — 441,356 D ↗
2024-09-30 Alpern Robert J Director A-Award A Stock Equivalent Units 37 197.48 7.3K 9,655 D ↗
2024-09-24 SALEKI-GERHARDT AZITA Officer G-Gift D Common Stock, $0.01 par value 25,630 0.00 — 194,348 D ↗
2024-08-05 GONZALEZ RICHARD A Director / Officer S-Sale D Common Stock, $0.01 par value 66,500 186.52 12.40M 446,599 — ↗
2024-07-17 GONZALEZ RICHARD A Director / Officer M-Exempt A Common Stock, $0.01 par value 119,418 79.02 9.44M 719,567 — ↗
2024-06-30 RAPP EDWARD J Director A-Award A Stock Equivalent Units 225 171.52 38.6K 26,170 — ↗
2024-06-30 Quaggin Susan E Director A-Award A Stock Equivalent Units 87 171.52 14.9K 236 — ↗
2024-06-30 Alpern Robert J Director A-Award A Stock Equivalent Units 43 171.52 7.4K 9,541 — ↗
2024-06-28 GONZALEZ RICHARD A Director / Officer G-Gift D Common Stock, $0.01 par value 6,000 0.00 — 513,099 — ↗
2024-05-03 WADDELL FREDERICK H Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 27,755 — ↗
2024-05-03 TILTON GLENN F Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 50,361 — ↗
2024-05-03 Roberts Rebecca B Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 12,525 — ↗
2024-05-03 RAPP EDWARD J Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 31,356 — ↗
2024-05-03 Quaggin Susan E Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 1,322 — ↗
2024-05-03 MEYER MELODY B Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 15,295 — ↗
2024-05-03 Hart Brett J Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 18,269 — ↗
2024-05-03 FREYMAN THOMAS C Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 125,548 — ↗
2024-05-03 Davis Jennifer L. Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 1,322 — ↗
2024-05-03 BURNSIDE WILLIAM H.L. Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 25,755 — ↗
2024-05-03 Alpern Robert J Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 34,443 — ↗
2024-05-03 AUSTIN ROXANNE S Director A-Award A Common Stock, $0.01 par value 1,322 0.00 — 37,255 — ↗
2024-03-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 212 182.10 38.6K 25,701 — ↗
2024-03-31 Quaggin Susan E Director A-Award A Stock Equivalent Units 82 182.10 14.9K 147 — ↗
2024-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 41 182.10 7.5K 9,408 — ↗
2024-03-20 Donoghoe Nicholas Officer S-Sale D Common Stock, $0.01 par value 21,082 176.30 3.72M 55,903 — ↗
2024-03-18 Stewart Jeffrey Ryan Officer S-Sale D Common Stock, $0.01 par value 5,099 179.03 912.9K 88,681 — ↗
2024-03-01 RICHMOND TIMOTHY J. Officer S-Sale D Common stock, $0.01 par value 30,288 177.71 5.38M 43,817 — ↗
2024-02-29 Siatis Perry C Officer S-Sale D Common Stock, $0.01 par value 6,504 177.05 1.15M 13,784 — ↗
2024-02-29 Michael Robert A. Officer M-Exempt D Option (Right to Buy) 10,140 54.86 556.3K 0 — ↗
2024-02-29 Buckbee Kevin K Officer S-Sale D Common Stock, $0.01 par value 5,144 176.65 908.7K 6,983 — ↗
2024-02-28 Thakkar Roopal Officer F-InKind D Common Stock, $0.01 par value 4,914 178.99 879.6K 23,259 — ↗
2024-02-28 Stewart Jeffrey Ryan Officer F-InKind D Common Stock, $0.01 par value 26,121 178.99 4.68M 93,780 — ↗
2024-02-28 Siatis Perry C Officer F-InKind D Common Stock, $0.01 par value 7,885 178.99 1.41M 20,288 — ↗
2024-02-28 SALEKI-GERHARDT AZITA Officer F-InKind D Common Stock, $0.01 par value 23,966 178.99 4.29M 219,978 — ↗
2024-02-28 Reents Scott T Officer F-InKind D Common Stock, $0.01 par value 11,634 178.99 2.08M 15,431 — ↗
2024-02-28 RICHMOND TIMOTHY J. Officer F-InKind D Common stock, $0.01 par value 23,847 178.99 4.27M 43,817 — ↗
2024-02-28 Michael Robert A. Officer F-InKind D Common Stock, $0.01 par value 37,638 178.99 6.74M 145,964 — ↗
2024-02-28 Hudson Thomas J Officer F-InKind D Common Stock, $0.01 par value 20,634 178.99 3.69M 107,267 — ↗
2024-02-28 GONZALEZ RICHARD A Director / Officer S-Sale D Common Stock, $0.01 par value 138,616 177.27 24.57M 519,099 — ↗
2024-02-28 Donoghoe Nicholas Officer F-InKind D Common Stock, $0.01 par value 16,771 178.99 3.00M 76,985 — ↗
2024-02-28 Buckbee Kevin K Officer F-InKind D Common Stock, $0.01 par value 5,339 178.99 955.6K 13,872 — ↗
2024-02-27 GONZALEZ RICHARD A Director / Officer G-Gift D Common Stock, $0.01 par value 1,670 0.00 — 770,489 — ↗
2024-02-23 Siatis Perry C Officer M-Exempt A Option (Right to buy) 7,315 149.62 1.09M 14,629 — ↗
2024-02-23 Reents Scott T Officer M-Exempt A Common Stock, $0.01 par value 14,140 61.36 867.6K 41,205 — ↗
2024-02-21 SALEKI-GERHARDT AZITA Officer M-Exempt D Option (Right to Buy) 52,870 58.88 3.11M 0 — ↗
2024-02-16 Thakkar Roopal Officer — D Option (Right to buy) 8,102 149.62 1.21M 0 — ↗
2024-02-16 Donoghoe Nicholas Officer — D Option (Right to buy) 17,555 149.62 2.63M 0 — ↗
2024-02-16 Buckbee Kevin K Officer — D Option (Right to buy) 6,076 149.62 909.1K 0 — ↗
2024-02-15 Thakkar Roopal Officer A-Award A Common Stock, $0.01 par value 2,140 0.00 — 41,313 D ↗
2024-02-15 Stewart Jeffrey Ryan Officer A-Award A Common Stock, $0.01 par value 9,268 0.00 — 119,901 — ↗
2024-02-15 Siatis Perry C Officer A-Award A Common Stock, $0.01 par value 2,138 0.00 — 20,537 — ↗
2024-02-15 SALEKI-GERHARDT AZITA Officer A-Award A Common Stock, $0.01 par value 6,060 0.00 — 243,944 — ↗
2024-02-15 Reents Scott T Officer A-Award A Option (Right to buy) 31,520 0.00 — 31,520 — ↗
2024-02-15 RICHMOND TIMOTHY J. Officer A-Award A Common stock, $0.01 par value 5,792 0.00 — 67,664 — ↗
2024-02-15 Michael Robert A. Officer A-Award A Common Stock, $0.01 par value 12,030 0.00 — 183,602 — ↗
2024-02-15 Hudson Thomas J Officer A-Award A Common Stock, $0.01 par value 5,348 0.00 — 127,901 — ↗
2024-02-15 GONZALEZ RICHARD A Director / Officer A-Award A Common Stock, $0.01 par value 30,300 0.00 — 772,159 — ↗
2024-02-15 Donoghoe Nicholas Officer A-Award A Common Stock, $0.01 par value 22,657 0.00 — 78,560 — ↗
2024-02-15 Buckbee Kevin K Officer A-Award A Common Stock, $0.01 par value 1,604 0.00 — 19,211 — ↗
2024-02-02 Siatis Perry C Officer D-Return D Common Stock, $0.01 par value 2,919 170.00 496.2K 10,377 — ↗
2023-12-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 250 154.97 38.7K 25,266 — ↗
2023-12-31 Quaggin Susan E Director A-Award A Stock Equivalent Units 64 154.97 9.9K 64 — ↗
2023-12-31 Alpern Robert J Director A-Award A Stock Equivalent Units 48 154.97 7.4K 9,285 — ↗
2023-12-26 Donoghoe Nicholas Officer S-Sale D Common Stock, $0.01 par value 2,912 154.72 450.5K 55,903 — ↗
2023-12-14 Thakkar Roopal Officer — D Common Stock, $0.01 par value 0 0.00 — 30,225 — ↗
2023-10-11 Quaggin Susan E — — — — 0 0.00 — 0 — ↗
2023-10-11 Davis Jennifer L. — — — — 0 0.00 — 0 — ↗
2023-09-30 RAPP EDWARD J Director A-Award A Stock Equivalent Units 259 149.06 38.6K 24,750 — ↗
2023-09-30 Alpern Robert J Director A-Award A Stock Equivalent Units 50 149.06 7.5K 9,139 — ↗
2023-09-25 GONZALEZ RICHARD A Director / Officer G-Gift D Common Stock, $0.01 par value 42,000 0.00 — 523,294 — ↗
2023-09-07 Alpern Robert J Director W-Will A Common Stock, $0.01 par value 129 0.00 — 33,121 — ↗
2023-08-01 GONZALEZ RICHARD A Director / Officer S-Sale D Common Stock, $0.01 par value 60,000 148.58 8.91M 565,294 — ↗
2023-07-31 GONZALEZ RICHARD A Director / Officer S-Sale D Common Stock, $0.01 par value 18,500 149.15 2.76M 625,294 — ↗
2023-06-30 RAPP EDWARD J Director A-Award A Stock Equivalent Units 287 134.73 38.7K 24,254 — ↗
2023-06-30 Alpern Robert J Director A-Award A Stock Equivalent Units 55 134.73 7.4K 9,001 — ↗
2023-06-29 Donoghoe Nicholas Officer — D Common Stock, $0.01 par value 0 0.00 — 58,815 — ↗
2023-05-11 Strom Carrie C Officer F-InKind D Common Stock, $0.01 par value 2,876 146.42 421.1K 28,024 — ↗
2023-05-05 WADDELL FREDERICK H Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 26,433 — ↗
2023-05-05 TILTON GLENN F Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 49,039 — ↗
2023-05-05 Roberts Rebecca B Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 11,203 — ↗
2023-05-05 RAPP EDWARD J Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 30,034 — ↗
2023-05-05 MEYER MELODY B Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 13,973 — ↗
2023-05-05 Hart Brett J Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 16,947 — ↗
2023-05-05 FREYMAN THOMAS C Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 124,226 — ↗
2023-05-05 BURNSIDE WILLIAM H.L. Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 24,433 — ↗
2023-05-05 Alpern Robert J Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 32,992 — ↗
2023-05-05 AUSTIN ROXANNE S Director A-Award A Common Stock, $0.01 par value 1,450 0.00 — 35,933 — ↗
2023-04-28 TILTON GLENN F Director M-Exempt D Stock Equivalent Units 2,230 151.12 337.0K 34,700 — ↗
2023-04-25 Sorg Elaine K. Officer M-Exempt D Option (Right to Buy) 6,130 144.54 886.0K 12,258 — ↗
2023-04-17 Sorg Elaine K. Officer S-Sale D Common Stock, $0.01 par value 500 162.04 81.0K 35,330 — ↗
2023-04-03 Sorg Elaine K. Officer S-Sale D Common Stock, $0.01 par value 15,002 160.03 2.40M 42,829 — ↗
2023-04-03 Siatis Perry C Officer M-Exempt D Option (Right to buy) 3,520 105.92 372.8K 3,520 — ↗
2023-03-31 RAPP EDWARD J Director A-Award A Stock Equivalent Units 243 159.37 38.7K 23,727 — ↗
2023-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 47 159.37 7.5K 8,856 — ↗
2023-03-13 Stewart Jeffrey Ryan Officer S-Sale D Common Stock, $0.01 par value 21,810 152.30 3.32M 92,256 — ↗
2023-03-05 Strom Carrie C Officer F-InKind D Common Stock, $0.01 par value 449 156.06 70.1K 30,900 — ↗
2023-03-03 GONZALEZ RICHARD A Director / Officer G-Gift D Common Stock, $0.01 par value 2,550 0.00 — 643,794 — ↗
2023-03-02 Strom Carrie C Officer F-InKind D Common Stock, $0.01 par value 810 155.27 125.8K 31,349 — ↗
2023-03-01 Sorg Elaine K. Officer S-Sale D Common Stock, $0.01 par value 15,003 155.00 2.33M 42,829 — ↗
2023-03-01 Siatis Perry C Officer S-Sale D Common Stock, $0.01 par value 11,330 153.06 1.73M 11,182 — ↗
2023-03-01 SALEKI-GERHARDT AZITA Officer M-Exempt A Common Stock, $0.01 par value 26,990 51.42 1.39M 226,839 — ↗
2023-03-01 Reents Scott T Officer S-Sale D Common Stock, $0.01 par value 15,092 153.06 2.31M 1,659 — ↗
2023-03-01 RICHMOND TIMOTHY J. Officer S-Sale D Common stock, $0.01 par value 16,746 153.62 2.57M 13,837 — ↗
2023-03-01 Buckbee Kevin K Officer — D Common Stock, $0.01 par value 0 0.00 — 7,163 — ↗
2023-02-28 Strom Carrie C Officer F-InKind D Common Stock, $0.01 par value 5,762 154.28 889.0K 32,159 — ↗
2023-02-28 Stewart Jeffrey Ryan Officer F-InKind D Common Stock, $0.01 par value 24,910 154.28 3.84M 92,256 — ↗
2023-02-28 Sorg Elaine K. Officer F-InKind D Common Stock, $0.01 par value 19,850 154.28 3.06M 42,829 — ↗
2023-02-28 Siatis Perry C Officer F-InKind D Common Stock, $0.01 par value 9,656 154.28 1.49M 22,512 — ↗
2023-02-28 SALEKI-GERHARDT AZITA Officer F-InKind D Common Stock, $0.01 par value 33,359 154.28 5.15M 199,849 — ↗
2023-02-28 Reents Scott T Officer F-InKind D Common Stock, $0.01 par value 12,683 154.28 1.96M 16,751 — ↗
2023-02-28 RICHMOND TIMOTHY J. Officer F-InKind D Common stock, $0.01 par value 35,111 154.28 5.42M 57,978 — ↗

Executive team

Top executives
EBIT / Employee
172.5K
Shares Outstanding
1.77B

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 Robert A. Michael Chairman of the Board and Chief Executive Officer 1.70M — 13.27M 3.20M 5.20M 9.16M 32.53M 50.62% ↗
2 2025 Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer 1.32M — 5.39M 1.30M 2.95M 4.48M 15.44M 43.34% ↗
3 2025 Scott T. Reents Executive Vice President, Chief Financial Officer 1.12M — 4.35M 1.05M 2.35M 3.48M 12.35M 43.74% ↗
4 2025 Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer 1.05M — 3.98M 959.8K 2.20M 2.60M 10.79M 45.78% ↗
5 2025 Roopal B. Thakkar Executive Vice President, Research & Development and Chief Scientific Officer 1.15M — 3.98M 959.8K 2.35M 1.48M 9.91M 49.84% ↗
6 2024 Richard A. Gonzalez Executive Chairman of the Board 1.60M — 15.00M 3.58M 4.41M 3.91M 28.50M 65.17% ↗
7 2024 Robert A. Michael Chairman of the Board and Chief Executive Officer 1.61M — 7.92M 1.89M 4.59M 2.49M 18.49M 53.02% ↗
8 2024 Robert A. Michael Chief Executive Officer 1.61M — 7.92M 1.89M 4.59M 2.49M 18.49M 53.02% ↗
9 2024 Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer 1.28M — 5.17M 1.23M 2.90M 3.47M 14.05M 45.55% ↗
10 2024 Scott T. Reents Executive Vice President, Chief Financial Officer 1.07M — 4.17M 993.8K 2.25M 2.51M 10.99M 46.94% ↗
11 2024 Timothy J. Richmond Executive Vice President, Chief Human Resources Officer 1.02M — 3.83M 914.3K 1.95M 2.58M 10.30M 46.07% ↗
12 2024 Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer 1.02M — 3.87M 924.2K 2.10M 2.00M 9.92M 48.39% ↗
13 2023 Richard A. Gonzalez Executive Chairman of the Board 1.70M — 13.70M 3.44M 3.50M 3.32M 25.66M 66.79% ↗
14 2023 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.70M — 13.70M 3.44M 3.50M 3.32M 25.66M 66.79% ↗
15 2023 Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer 1.19M — 4.19M 1.05M 2.53M 6.39M 15.35M 34.15% ↗
16 2023 Robert A. Michael Chief Executive Officer 1.43M — 5.44M 1.37M 3.00M 3.21M 14.44M 47.12% ↗
17 2023 Robert A. Michael President and Chief Operating Officer 1.43M — 5.44M 1.37M 3.00M 3.21M 14.44M 47.12% ↗
18 2023 Robert A. Michael Chairman of the Board and Chief Executive Officer 1.43M — 5.44M 1.37M 3.00M 3.21M 14.44M 47.12% ↗
19 2023 Scott T. Reents Executive Vice President, Chief Financial Officer 973.1K — 4.03M 1.01M 1.85M 2.32M 10.19M 49.49% ↗
20 2023 Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer 941.0K — 2.74M 687.6K 1.85M 3.08M 9.30M 36.86% ↗
21 2022 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.70M — 15.30M 3.60M 3.93M 1.76M 26.29M 71.90% ↗
22 2022 Richard A. Gonzalez Executive Chairman of the Board 1.70M — 15.30M 3.60M 3.93M 1.76M 26.29M 71.90% ↗
23 2022 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 1.29M — 5.53M 1.30M 2.25M 1.24M 11.61M 58.81% ↗
24 2022 Robert A. Michael Chief Executive Officer 1.33M — 4.68M 1.10M 2.51M 159.0K 9.77M 59.08% ↗
25 2022 Robert A. Michael Vice Chairman and President 1.33M — 4.68M 1.10M 2.51M 159.0K 9.77M 59.08% ↗
26 2022 Robert A. Michael President and Chief Operating Officer 1.33M — 4.68M 1.10M 2.51M 159.0K 9.77M 59.08% ↗
27 2022 Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer 1.11M — 5.61M 849.6K 1.65M 402.4K 9.63M 67.14% ↗
28 2022 Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer 866.4K — 5.40M 799.6K 1.44M 494.3K 9.00M 68.89% ↗
29 2022 Azita Saleki-Gerhardt Executive Vice President, Operations 866.4K — 5.40M 799.6K 1.44M 494.3K 9.00M 68.89% ↗
30 2022 Scott T. Reents Executive Vice President, Chief Financial Officer 753.1K — 2.10M 259.9K 1.40M 1.10M 5.62M 42.06% ↗
31 2021 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.70M — 12.57M 3.13M 4.91M 1.60M 23.91M 65.69% ↗
32 2021 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 1.25M — 4.26M 1.06M 2.64M 3.20M 12.41M 42.87% ↗
33 2021 Robert A. Michael President and Chief Operating Officer 1.13M — 4.26M 1.06M 2.63M 2.59M 11.67M 45.60% ↗
34 2021 Robert A. Michael Vice Chairman and President 1.13M — 4.26M 1.06M 2.63M 2.59M 11.67M 45.60% ↗
35 2021 Robert A. Michael Vice Chairman, Finance and Commercial Operations and CFO 1.13M — 4.26M 1.06M 2.63M 2.59M 11.67M 45.60% ↗
36 2021 Michael E. Severino Vice Chairman and President 1.41M — 4.26M 1.06M 2.70M 1.62M 11.05M 48.15% ↗
37 2021 Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer 1.07M — 2.84M 707.8K 2.05M 2.34M 9.01M 39.35% ↗
38 2020 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.69M — 11.64M 2.78M 4.91M 2.98M 24.01M 60.09% ↗
39 2020 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 1.21M — 5.82M 1.39M 2.55M 6.15M 17.13M 42.12% ↗
40 2020 Carlos Alban Vice Chairman, Chief Commercial Officer 1.21M — 5.82M 1.39M 2.48M 5.95M 16.85M 42.80% ↗
41 2020 Robert A. Michael Vice Chairman, Finance and Commercial Operations and CFO 1.07M — 5.41M 1.29M 2.11M 3.62M 13.49M 49.63% ↗
42 2020 Robert A. Michael Executive Vice President, Chief Financial Officer 1.07M — 5.41M 1.29M 2.11M 3.62M 13.49M 49.63% ↗
43 2020 Robert A. Michael Vice Chairman and President 1.07M — 5.41M 1.29M 2.11M 3.62M 13.49M 49.63% ↗
44 2020 Michael E. Severino Vice Chairman and President 1.37M — 5.82M 1.39M 2.70M 2.13M 13.41M 53.79% ↗
45 2019 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.65M — 8.89M 2.25M 4.34M 4.49M 21.61M 51.52% ↗
46 2019 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 1.18M — 3.40M 859.4K 2.40M 7.31M 15.14M 28.13% ↗
47 2019 Carlos Alban Vice Chairman, Chief Commercial Officer 1.18M — 3.09M 781.3K 2.40M 6.96M 14.41M 26.88% ↗
48 2019 Michael E. Severino Vice Chairman and President 1.33M — 3.20M 808.6K 2.40M 1.77M 9.51M 42.15% ↗
49 2019 Robert A. Michael Vice Chairman, Finance and Commercial Operations and CFO 906.9K — 2.70M 683.6K 1.80M 2.68M 8.77M 38.62% ↗
50 2019 Robert A. Michael Executive Vice President, Chief Financial Officer 906.9K — 2.70M 683.6K 1.80M 2.68M 8.77M 38.62% ↗
51 2018 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.65M — 11.51M 2.76M 3.90M 1.47M 21.28M 67.05% ↗
52 2018 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 1.04M — 4.13M 991.7K 1.95M 3.26M 11.38M 45.03% ↗
53 2018 Carlos Alban Vice Chairman, Chief Commercial Officer 1.02M — 4.01M 961.2K 1.84M 1.16M 8.98M 55.29% ↗
54 2018 William J. Chase Executive Vice President, Finance and Administration 1.04M — 4.13M 991.7K 1.95M 605.2K 8.72M 58.76% ↗
55 2018 Michael E. Severino Vice Chairman and President 1.10M — 4.18M 1.00M 1.82M 510.4K 8.61M 60.16% ↗
56 2018 Robert A. Michael Senior Vice President, Chief Financial Officer 553.7K — 724.0K 173.7K 950.0K 717.5K 3.12M 28.78% ↗
57 2018 Robert A. Michael Executive Vice President, Chief Financial Officer 553.7K — 724.0K 173.7K 950.0K 717.5K 3.12M 28.78% ↗
58 2017 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.64M — 9.61M 2.56M 4.33M 4.49M 22.63M 53.77% ↗
59 2017 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 1.01M — 7.68M 981.0K 1.95M 3.35M 14.98M 57.83% ↗
60 2017 Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary 1.01M — 7.68M 981.0K 1.95M 3.35M 14.98M 57.83% ↗
61 2017 Carlos Alban Executive Vice President, Global Commercial Operations 947.5K — 3.52M 938.4K 1.84M 5.09M 12.33M 36.16% ↗
62 2017 Carlos Alban Vice Chairman, Chief Commercial Officer 947.5K — 3.52M 938.4K 1.84M 5.09M 12.33M 36.16% ↗
63 2017 William J. Chase Executive Vice President, Finance and Administration 1.01M — 3.68M 981.0K 1.95M 4.42M 12.04M 38.71% ↗
64 2017 William J. Chase Executive Vice President, Chief Financial Officer 1.01M — 3.68M 981.0K 1.95M 4.42M 12.04M 38.71% ↗
65 2017 Michael E. Severino Executive Vice President, Research & Development and Chief Scientific Officer 1.00M — 3.68M 981.0K 1.96M 772.9K 8.40M 55.54% ↗
66 2017 Michael E. Severino Vice Chairman and President 1.00M — 3.68M 981.0K 1.96M 772.9K 8.40M 55.54% ↗
67 2016 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.60M — 9.32M 2.36M 3.60M 4.09M 20.97M 55.69% ↗
68 2016 William J. Chase Executive Vice President, Chief Financial Officer 979.4K — 3.48M 882.5K 1.63M 1.86M 8.83M 49.44% ↗
69 2016 William J. Chase Executive Vice President, Finance and Administration 979.4K — 3.48M 882.5K 1.63M 1.86M 8.83M 49.44% ↗
70 2016 Laura J. Schumacher Vice Chairman, External Affairs and Chief Legal Officer 979.4K — 2.86M 725.7K 1.63M 2.02M 8.22M 43.69% ↗
71 2016 Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary 979.4K — 2.86M 725.7K 1.63M 2.02M 8.22M 43.69% ↗
72 2016 Carlos Alban Vice Chairman, Chief Commercial Officer 920.1K — 2.92M 738.8K 1.51M 2.13M 8.22M 44.49% ↗
73 2016 Carlos Alban Executive Vice President, Global Commercial Operations 920.1K — 2.92M 738.8K 1.51M 2.13M 8.22M 44.49% ↗
74 2016 Henry O. Gosebruch Executive Vice President, Chief Strategy Officer 894.5K 1.00M 3.07M 776.6K 1.33M 334.2K 7.40M 51.94% ↗
75 2016 Michael E. Severino Vice Chairman and President 961.0K — 3.36M 850.9K 1.60M 476.6K 7.24M 58.12% ↗
76 2016 Michael E. Severino Executive Vice President, Research & Development and Chief Scientific Officer 961.0K — 3.36M 850.9K 1.60M 476.6K 7.24M 58.12% ↗
77 2015 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.59M — 9.75M 3.26M 2.98M 3.24M 20.81M 62.50% ↗
78 2015 William J. Chase Executive Vice President, Chief Financial Officer 950.4K — 3.30M 1.10M 1.36M 903.0K 7.61M 57.82% ↗
79 2015 Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary 951.5K — 3.07M 1.03M 1.36M 894.5K 7.31M 56.14% ↗
80 2015 Carlos Alban Executive Vice President, Commercial Operations 888.5K — 3.04M 1.02M 1.20M 909.4K 7.05M 57.47% ↗
81 2015 Carlos Alban Executive Vice President, Global Commercial Operations 888.5K — 3.04M 1.02M 1.20M 909.4K 7.05M 57.47% ↗
82 2015 Michael E. Severino Executive Vice President, Research & Development and Chief Scientific Officer 918.1K — 3.11M 1.04M 1.24M 294.8K 6.60M 62.88% ↗
83 2014 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.60M — 8.38M 2.76M 3.50M 5.77M 22.01M 50.63% ↗
84 2014 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.60M — 8.38M 2.76M 3.50M 723.6K 22.01M 50.63% ↗
85 2014 Michael E. Severino Executive Vice President, Research Development and Chief Scientific Officer 503.8K 1.00M 7.71M 734.9K 1.20M 205.1K 11.54M 73.16% ↗
86 2014 Michael E. Severino Executive Vice President, Research & Development and Chief Scientific Officer 503.8K 1.00M 7.71M 734.9K 1.20M 394.0K 11.54M 73.16% ↗
87 2014 Carlos Alban Executive Vice President, Commercial Operations 844.5K — 2.43M 801.1K 1.30M 3.89M 9.26M 34.88% ↗
88 2014 Carlos Alban Executive Vice President, Commercial Operations 844.5K — 2.43M 801.1K 1.30M 1.59M 9.26M 34.88% ↗
89 2014 Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary 957.6K — 2.81M 925.4K 1.49M 2.87M 9.05M 41.25% ↗
90 2014 Laura J. Schumacher Executive Vice President, Business Development, External Affairs and General Counsel 957.6K — 2.81M 925.4K 1.49M 402.1K 9.05M 41.25% ↗
91 2014 William J. Chase Executive Vice President, Chief Financial Officer 923.7K — 2.76M 911.6K 1.49M 121.9K 7.92M 46.40% ↗
92 2014 William J. Chase Executive Vice President, Chief Financial Officer 923.7K — 2.76M 911.6K 1.49M 1.83M 7.92M 46.40% ↗
93 2013 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.50M — 9.25M 3.62M 3.30M 513.2K 18.18M 70.77% ↗
94 2013 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 1.50M — 9.25M 3.62M 3.30M 471.6K 18.18M 70.77% ↗
95 2013 Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary 900.0K — 2.56M 1.04M 1.29M 1.21M 7.00M 51.33% ↗
96 2013 Laura J. Schumacher Executive Vice President, Business Development, External Affairs and General Counsel 900.0K — 2.56M 1.04M 1.29M 270.4K 7.00M 51.33% ↗
97 2013 Carlos Alban Executive Vice President, Commercial Operations 710.0K — 2.03M 795.8K 1.03M 565.0K 5.14M 55.11% ↗
98 2013 Carlos Alban Executive Vice President, Commercial Operations 710.0K — 2.03M 795.8K 1.03M 148.1K 5.14M 55.11% ↗
99 2013 William J. Chase Executive Vice President, Chief Financial Officer 790.0K — 2.03M 795.8K 1.10M 392.6K 5.11M 55.36% ↗
100 2013 William J. Chase Executive Vice President, Chief Financial Officer 790.0K — 2.03M 795.8K 1.10M 76.8K 5.11M 55.36% ↗
101 2013 Timothy J. Richmond 545.0K — 1.53M 598.0K 525.0K 51.8K 3.30M 64.40% ↗
102 2012 Laura J. Schumacher Executive Vice President, General Counsel, and Corporate Secretary 831.7K 1.10M 4.49M 576.8K 1.27M 156.3K 10.19M 49.68% ↗
103 2012 Laura J. Schumacher Executive Vice President, Business Development, External Affairs and General Counsel 831.7K 1.10M 4.49M 576.8K 1.27M 156.3K 10.19M 49.68% ↗
104 2012 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 863.9K — 3.34M 729.6K 2.50M 449.3K 7.95M 51.22% ↗
105 2012 Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group 863.9K — 3.34M 729.6K 2.50M 449.3K 7.95M 51.22% ↗
106 2012 Carlos Alban Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations 615.8K 300.0K 2.70M 331.5K 675.0K 104.3K 6.53M 46.46% ↗
107 2012 Carlos Alban Executive Vice President, Commercial Operations 615.8K 300.0K 2.70M 331.5K 675.0K 104.3K 6.53M 46.46% ↗
108 2012 John M. Leonard, M.D. Senior Vice President, Pharmaceuticals, Research and Development 640.2K — 2.23M 224.4K 515.6K 149.1K 5.48M 44.80% ↗
109 2012 William J. Chase Vice President, Licensing and Acquisitions 398.9K 500.0K 2.11M 162.1K 500.0K 45.7K 4.22M 53.93% ↗
110 2012 William J. Chase Executive Vice President, Chief Financial Officer 398.9K 500.0K 2.11M 162.1K 500.0K 45.7K 4.22M 53.93% ↗
111 2011 Laura J. Schumacher Executive Vice President, General Counsel, and Corporate Secretary 827.5K — 1.91M 358.2K 1.18M 158.3K 5.57M 40.66% ↗
112 2011 Laura J. Schumacher Executive Vice President, Business Development, External Affairs and General Counsel 827.5K — 1.91M 358.2K 1.18M 158.3K 5.57M 40.66% ↗
113 2011 Richard A. Gonzalez Chairman of the Board and Chief Executive Officer 825.0K — 1.83M 343.3K 1.23M 445.4K 5.55M 39.07% ↗
114 2011 Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group 825.0K — 1.83M 343.3K 1.23M 445.4K 5.55M 39.07% ↗
115 2011 Carlos Alban Executive Vice President, Commercial Operations 602.5K — 1.51M 285.3K 610.0K 106.2K 3.89M 46.23% ↗
116 2011 Carlos Alban Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations 602.5K — 1.51M 285.3K 610.0K 106.2K 3.89M 46.23% ↗
117 2011 John M. Leonard, M.D. Senior Vice President, Pharmaceuticals, Research and Development 636.5K — 1.03M 194.4K 475.5K 141.2K 3.50M 35.12% ↗
118 2011 William J. Chase Vice President, Licensing and Acquisitions 375.0K — 628.9K 118.4K 330.0K 50.7K 1.82M 41.07% ↗
119 2011 William J. Chase Executive Vice President, Chief Financial Officer 375.0K — 628.9K 118.4K 330.0K 50.7K 1.82M 41.07% ↗
120 2010 Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group 742.1K 300.0K 5.14M — 848.9K 262.0K 7.60M 67.56% ↗
121 2010 Laura J. Schumacher Executive Vice President, General Counsel, and Corporate Secretary 823.3K — 3.90M 535.9K 1.10M 138.0K 7.13M 62.26% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-03-23 DEFA14A ↗
2026-03-23 DEF 14A ↗
2026-03-09 PRE 14A ↗
2025-03-24 DEFA14A ↗
2025-03-24 DEF 14A ↗
2025-03-10 PRE 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-08 10-Q ↗
2026-04-29 SC 13G ↗
2026-04-29 8-K ↗
2026-04-03 8-K ↗
2026-04-02 4 ↗
2026-04-02 4 ↗
2026-04-02 4 ↗
2026-03-26 SC 13G/A ↗
2026-03-23 DEFA14A ↗
2026-03-23 DEF 14A ↗

Executive team

NameTitleCompensationGender
Robert A. Michael Chief Executive Officer & Chairman of the Board 7M male
Jeffrey Ryan Stewart Executive Vice President & Chief Commercial Officer 5M male
Azita Saleki-Gerhardt Executive Vice President & Chief Operating Officer 4M —
Scott T. Reents Executive Vice President & Chief Financial Officer 4M male
Demetris D. Crum Executive Vice President & Chief Human Resources Officer 4M male
Roopal Thakkar Executive Vice President of Research and Development & Chief Scientific Officer 4M —
Jonathon Sedgwick Senior VP & Global Head of Discovery Research — —
Latif Akintade Senior Vice President of Medical Affairs & Health Economics Outcomes Research — —
Linda Ray Senior VP & Chief Information Officer — female
Nicholas J. Donoghoe Executive Vice President and Chief Business & Strategy Officer — —
Nisha Patel Burns Senior VP of AbbVie & President of Specialty and U.S. Therapeutics Operations — female
Perry C. Siatis Executive Vice President, General Counsel & Secretary — male
ESG Rating
B
DRUG MANUFACTURERS - GENERAL
2022
E (Environmental)
66.7 / 68.7
Company / Sector avg.
S (Social)
62.2 / 66.7
Company / Sector avg.
G (Governance)
69.0 / 67.9
Company / Sector avg.
ESG Total
66.0 / 67.7
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
Transaction Date Disclosed Senator State Owner Type Amount Link
2025-08-22 2025-09-12 John Boozman AR Joint Sale (Partial) $1,001 - $15,000 ↗
2025-08-22 2025-09-13 John Boozman AR Joint Sale $1,001 - $15,000 ↗
2025-08-11 2025-09-12 John Boozman AR Joint Sale (Partial) $1,001 - $15,000 ↗
2025-08-11 2025-09-13 John Boozman AR Joint Sale $1,001 - $15,000 ↗
2024-04-03 2024-05-15 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2024-01-19 2024-02-14 Tommy Tuberville AL Joint Sale (Full) $1,001 - $15,000 ↗
2023-11-20 2023-12-15 Tommy Tuberville AL Joint Sale (Full) $1,001 - $15,000 ↗
2023-10-17 2023-11-16 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2023-04-03 2023-05-11 Tommy Tuberville AL Joint Sale (Partial) $1,001 - $15,000 ↗
2022-03-30 2022-04-08 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2022-01-21 2022-02-14 Tommy Tuberville AL Joint Sale (Full) $1,001 - $15,000 ↗
2022-01-18 2022-02-03 Thomas R. Carper DE Spouse Sale (Partial) $1,001 - $15,000 ↗
2020-11-20 2021-05-17 Thomas R. Carper DE Spouse Purchase $1,001 - $15,000 ↗
2020-08-21 2020-09-08 Jerry Moran KS Spouse Sale (Full) $1,001 - $15,000 ↗
2020-07-09 2021-05-17 Thomas R. Carper DE Spouse Sale (Partial) $1,001 - $15,000 ↗
2020-04-14 2020-05-01 Kelly Loeffler GA Spouse Sale (Full) $250,001 - $500,000 ↗
2020-04-14 2020-05-08 David Perdue — Joint Sale (Full) $15,001 - $50,000 ↗
2020-04-07 2020-05-01 Kelly Loeffler GA Spouse Purchase $15,001 - $50,000 ↗
2020-04-07 2020-05-01 Kelly Loeffler GA Spouse Purchase $1,001 - $15,000 ↗
2020-03-24 2020-04-01 Thomas R. Carper DE Spouse Purchase $1,001 - $15,000 ↗
House Trading Activity
Transaction Date Disclosed Representative District Owner Type Amount Link
2025-12-18 2026-01-16 Julie Johnson TX32 Joint Sale $1,001 - $15,000 ↗
2025-12-08 2026-01-13 Julia Letlow LA05 — Sale (Full) $1,001 - $15,000 ↗
2025-11-13 2025-12-12 Julie Johnson TX32 Joint Sale $1,001 - $15,000 ↗
2025-10-31 2025-11-24 Lisa McClain MI09 Spouse Sale $1,001 - $15,000 ↗
2025-10-30 2025-11-24 Lisa McClain MI09 Spouse Sale $1,001 - $15,000 ↗
2025-10-30 2025-11-24 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-08-14 2025-09-12 Julie Johnson TX32 Joint Sale $1,001 - $15,000 ↗
2025-08-04 2025-09-12 Ro Khanna CA17 Spouse Purchase $1,000 - $15,000 ↗
2025-08-04 2025-08-15 Marjorie Taylor Greene GA14 — Purchase $1,001 - $15,000 ↗
2025-07-22 2025-08-13 Lisa McClain MI09 Spouse Sale (Partial) $1,001 - $15,000 ↗
2025-07-22 2025-08-14 Lisa McClain MI09 Spouse Sale $1,001 - $15,000 ↗
2025-07-22 2025-08-13 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-07-22 2025-08-14 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-07-11 2025-08-20 Ritchie Torres NY15 — Sale (Full) $1,001 - $15,000 ↗
2025-06-17 2025-08-13 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-06-17 2025-08-14 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-05-22 2025-06-12 Josh Gottheimer NJ05 Joint Purchase $1,001 - $15,000 ↗
2025-05-15 2025-06-10 Rob Bresnahan PA08 — Purchase $1,001 - $15,000 ↗
2025-05-05 2025-05-07 Marjorie Taylor Greene GA14 — Purchase $1,001 - $15,000 ↗
2025-04-28 2026-01-13 Julia Letlow LA05 — Purchase $1,001 - $15,000 ↗
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General